The influence of the “cancer” label on perceptions and management decisions for low-grade prostate cancer

Author:

Berlin Alejandro1ORCID,Ramotar Matthew1,Santiago Anna T2,Liu Zhihui2,Li Joyce3,Wolinsky Howard4,Wallis Christopher J D5,Chua Melvin L K6,Paner Gladell P7,van der Kwast Theodorus8,Cooperberg Matthew R9,Vickers Andrew J10,Urbach David R11,Eggener Scott E12

Affiliation:

1. Department of Radiation Oncology, University of Toronto; Radiation Medicine Program, Princess Margaret Cancer Centre; TECHNA Institute, University Health Network , Toronto, ON, Canada

2. Department of Biostatistics, Princess Margaret Cancer Centre; Dalla Lana School of Public Health, University of Toronto , Toronto, ON, Canada

3. The University of Western Ontario , London, ON, Canada

4. AnCan Active Surveillance Virtual Support Group; The Active Surveillor Newsletter , Chicago, IL, USA

5. Division of Urology, Department of Surgery, University of Toronto, Mount Sinai Hospital, and University Hospital Network , Toronto, ON, Canada

6. Divisions of Radiation Oncology and Medical Sciences, National Cancer Centre Singapore; Oncology Academic Programme, Duke-NUS Medical School , Singapore

7. Departments of Pathology and Surgery, University of Chicago. Chicago , IL, USA

8. Laboratory Medicine Program, University Health Network , Toronto, ON, Canada

9. Departments of Urology and Epidemiology and Biostatistics, University of California San Francisco Comprehensive Cancer Center , San Francisco, CA, USA

10. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY, USA

11. Institute for Clinical Evaluative Sciences (ICES), Department of Surgery, University of Toronto; Perioperative Services, Women’s College Hospital and Research Institute, Toronto , ON, Canada

12. Section of Urology, Department of Surgery, The University of Chicago Comprehensive Cancer Center, Chicago , IL, USA

Abstract

Abstract Background Grade Group 1 (GG1) prostate cancer should be managed with active surveillance (AS). Global uptake of AS remains disappointingly slow and heterogeneous. Removal of cancer labels has been proposed to reduce GG1 overtreatment. We sought to determine the impact of GG1 disease terminology on individual’s perceptions and decision making. Methods Discrete choice experiments were conducted on 3 cohorts: healthy men, canonical partners (partners), and patients with GG1 (patients). Participants reported preferences in a series of vignettes with 2 scenarios each, permuting key opinion leader–endorsed descriptors: biopsy (adenocarcinoma, acinar neoplasm, prostatic acinar neoplasm of low malignant potential [PAN-LMP], prostatic acinar neoplasm of uncertain malignant potential), disease (cancer, neoplasm, tumor, growth), management decision (treatment, AS), and recurrence risk (6%, 3%, 1%, <1%). Influence on scenario selection were estimated by conditional logit models and marginal rates of substitution. Two additional validation vignettes with scenarios portraying identical descriptors except the management options were embedded into the discrete choice experiments. Results Across cohorts (194 healthy men, 159 partners, and 159 patients), noncancer labels PAN-LMP or prostatic acinar neoplasm of uncertain malignant potential and neoplasm, tumor, or growth were favored over adenocarcinoma and cancer (P < .01), respectively. Switching adenocarcinoma and cancer labels to PAN-LMP and growth, respectively, increased AS choice by up to 17%: healthy men (15%, 95% confidence interval [CI] = 10% to 20%, from 76% to 91%, P < .001), partners (17%, 95% CI = 12% to 24%, from 65% to 82%, P < .001), and patients (7%, 95% CI = 4% to 12%, from 75% to 82%, P = .063). The main limitation is the theoretical nature of questions perhaps leading to less realistic choices. Conclusions “Cancer” labels negatively affect perceptions and decision making regarding GG1. Relabeling (ie, avoiding word “cancer”) increases proclivity for AS and would likely improve public health.

Funder

Abbvie CARO

Canadian Association of Radiation Oncology

Uro-Oncologic Radiation

Princess Margaret Cancer Foundation

National Institutes of Health

National Cancer Institute

Memorial Sloan Kettering Cancer Center

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3